Skip to content

Clip Closure of Mucosal Defects After Endoscopic Mucosal Resection.

Clip Closure of Mucosal Defects After Endoscopic Mucosal Resection of Large Colorectal Lesions as Prophylaxis of Delayed Haemorrhage.

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT02765022
Enrollment
235
Registered
2016-05-06
Start date
2016-05-31
Completion date
2018-10-31
Last updated
2019-01-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Clip, Endoscopic Resection, Haemorrhage, Non-pedunculated Lesions

Brief summary

An simple-blind, randomized study, to evaluate the efficacy and safety of complete closure with clips of mucosal defects after endoscopic mucosal resection (EMR) of large non-pedunculated colorectal lesions (≥ 2 cm) as prophylaxis of delayed bleeding.

Interventions

Complete clip closure of secondary lesions after the endoscopic mucosal resection

PROCEDURENo clip closure

Observation: no clip closure of secondary lesions after the endoscopic mucosal resection

Sponsors

Fundacion Miguel Servet
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
PREVENTION
Masking
SINGLE (Subject)

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* 18 years and older * Clinical indication of endoscopic mucosal resection for large-sized (≥ 2cm) non-pedunculated colorectal lesions. * Medium-high risk of delayed bleeding (DB risk score ≥ 4) * Informed consent.

Exclusion criteria

* Patients with colorectal non-pedunculated lesions without endoscopic mucosal resection indication. * Lesions resected by endoscopic submucosal resection. * Incomplete resections. * Resections with suspected deep submucosal invasion. * Mucosal defects treated with clips for known or suspected damage to the muscle layer. * Lesions with low risk of delayed bleeding (DB risk score ≤3). * Patients with any other medical, geographic or social condition, deemed by the Investigator to be likely to interfere with a patient's ability to sign informed consent, cooperate and participate in the study, or interfere with the interpretation of the results.

Design outcomes

Primary

MeasureTime frame
Delayed hemorrhage15 days post-EMR

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Mar 2, 2026